NOV 08, 2013 12:00 PM PST

Childhood cancer with various genomic assay including whole genome sequencing

Speakers
  • Scientific Projects Manager, TARGET, NCI Office of Cancer Genomics
    Biography
      Dr. Guidry Auvil is a scientific program officer overseeing large-scale genomics efforts within the Office of Cancer Genomics at the National Cancer Institute.  She completed her doctoral work in the Biomedical Sciences program and received her PhD in tumor biology at Georgetown University.  In graduate school, Dr. Guidry Auvil studied the effects of cellular adhesion molecules on breast cancer bone metastases and holds a patent for a viable small molecule inhibitor of cadherin-11, which is currently being tested for various therapeutic applications. She also has a background in clinical and psychosocial research and project management in both the biotechnology and healthcare sectors. Dr. Guidry Auvil now manages the NCI pediatric cancer genomics initiative, Therapeutically Applicable Research to Generate Effective Treatments (TARGET).    
      <br />

    Abstract:

    The NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) is a comprehensive genomic characterization initiative to determine the molecular changes that drive the development and progression of certain childhood cancers. TARGET seeks to improve treatment of these cancers through identification of valid molecular targets, in and across each disease, and ultimately lead to the rapid development of novel, more effective therapies. The TARGET projects include primarily high-risk for relapse cases. Most TARGET disease groups also have relapse samples available for study, thereby allowing the determination of changes that occur during the disease progression. To accelerate translation into the clinic, TARGET data is readily available to the research community for further investigation. There are currently around 2,000 TARGET BAM files from next generation platforms currently available to investigators, and additional sequencing files are regularly being submitted to expand the TARGET datasets. All TARGET cases have either whole genome or exome sequencing of matched tumor and normal pairs (relapse sample when available), and transcriptome sequences exist for most TARGET cases as well. In addition, all TARGET cases have clinical annotation, array-based gene expression and copy number data available to researchers, most also have methylation profiles, to allow for a more complete understanding of the molecular basis of these childhood cancers. Some projects have further included miRNA characterization data as well.


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    Loading Comments...
    Show Resources